Synthetic DNA & RNA Patents: Leaders, Trends & White Space 2026
- 8.5% concentration at the very top. The five leading assignees hold 17,738 of 207,667 records in scope — a real edge, but not a lock on the field.
- Filing cooled from a 2021 peak. Publications ran from 980 in 2021 to 463 in 2024, a -53% move over three years, though 2025-26 counts are still filling in.
- Momentum is thinning even among leaders. Several of the most active historical filers show single-digit output in the latest year and year-on-year drops as steep as -91%.
Filing growth compares 2021 (980 records) with 2024 (463) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 207,667 records in scope (CR5), not by the ranked leaders only.
What the synthetic DNA & RNA patent record shows
Synthetic DNA and RNA work sits at the intersection of genetic engineering, enzymatic synthesis and diagnostic measurement. The dataset behind this page spans 207,667 published records filed between 2015 and 2026, captured through claims and descriptions referencing synthetic DNA alongside sequence reads, molecular targets, expression levels, biomarkers or variant detection. That combination pulls in everything from vector construction and enzyme engineering to nucleic-acid based diagnostics, which is why the IPC composition below spreads across microorganism engineering, peptide chemistry, fermentation and material analysis rather than clustering in one class.
Reading the record straight: no single assignee dominates. The leading company holds 4,818 records against a total of 207,667, and the ranked field runs a long tail from there. That structure rewards a targeted freedom-to-operate search over an assumption that one or two firms control the space.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 207,667-record set: publication activity by year, and where those records sit across IPC subclasses. Because a record can carry more than one classification, the class shares add up to more than the record total — that is expected, not an error.
Publications by year
Publications rose to a peak of 980 in 2021, then eased to 463 by 2024, a -53% move over that span. 2017 opened at 802. Treat 2025 and 2026 as undercounted: publication trails filing by roughly 18 months, so the most recent years will keep filling in as data catches up.
Technology composition by IPC subclass
C12N (microorganisms and genetic engineering) leads at 6.2% of the 207,667 records in scope, followed by C12Q (enzyme/DNA-based measuring and testing) at 4.3% and C07K (peptides and proteins) at 3.2%. A61K, C12P, G01N, C07H and A61P each sit below 3%, showing that therapeutic formulation, fermentation-based synthesis and analytical measurement are present but secondary to the core engineering and testing classes.
Shares are the percentage of the 207,667 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Synthetic DNA & RNA Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about synthetic dna & rna patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaThe patents everyone else is built on
Functional nucleic acid ligands to fluorescent proteins
US20090197271A1, filed by Cornell Research Foundation, describes a nucleic acid aptamer with a domain that binds a fluorescent protein, forming a molecular complex usable for detecting and locating a molecular target. The filing also covers the constructed DNA molecule, expression systems and host cells built around that complex, plus a two-part system pairing the aptamer-encoding DNA with a second DNA molecule encoding the fluorescent protein it binds.Published 2009-08-06 — now well inside the citation network the field's later diagnostic and imaging work draws on.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US5130238A | Enhanced nucleic acid amplification process | 3,226 |
| 2 | US6013516A | Vector and method of use for nucleic acid delivery to non-dividing cells | 1,987 |
| 3 | US5409818A | Nucleic acid amplification process | 1,796 |
| 4 | US6300064B1 | Protein/(poly)peptide libraries | 1,760 |
| 5 | US20010053519A1 | Oligonucleotides | 1,693 |
| 6 | US6582908B2 | Oligonucleotides | 1,598 |
| 7 | US5316931A | Plant viral vectors having heterologous subgenomic promoters for systemic expression of foreign genes | 1,475 |
| 8 | WO1998044151A1 | Method of nucleic acid amplification | 1,455 |
| 9 | WO1998053059A1 | Nucleic acid binding proteins | 1,358 |
| 10 | WO1998053058A1 | Nucleic acid binding proteins | 1,323 |
Citation counts favour older filings simply because they have had more time to accumulate them — read this as a map of foundational influence, not of current commercial importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the filing pattern actually tells you
Three findings shape how a competitive or freedom-to-operate review should be scoped in this space.
The top of the field is thin, not dominant
The five leading assignees combine for 17,738 records, 8.5% of all 207,667 records in scope. Extending to the top ten adds only another five points, to 13.3%. That leaves the large majority of filing activity spread across a long tail of universities, agri-biotech firms and pharma players rather than locked up by a handful of blockers.
Peak filing has passed, on the data available so far
Publications peaked at 980 in 2021 and had fallen to 463 by 2024, a -53% change over that span. That decline sits inside the complete-year data; 2025 and 2026 numbers will rise as publication catches up with filing, so treat the recent-year figures as a floor, not a ceiling.
Engineering and testing classes carry the field
C12N (microorganisms and genetic engineering) and C12Q (enzyme and DNA-based measuring) together account for the largest shares of the record set, at 6.2% and 4.3% respectively. Diagnostic and analytical classes like G01N and C07H trail well behind, suggesting measurement and detection methods built on synthetic constructs are less claim-dense than the core engineering work itself.
Filing strategy still runs through the US first
The United States receives more filings in this dataset than the EPO, WIPO/PCT, Australia, Canada and New Zealand combined among the offices tracked, with EPO and PCT the clear second tier. That pattern matters for where a freedom-to-operate search should start, and where a competitor is least likely to have covered every jurisdiction.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to synthetic dna & rna patent landscape, with the prior art for and against each one.
The assignee landscape
The ranked list covers 100 assignees by record count, led by a mix of agri-biotech, pharma and university technology-transfer offices. None of them controls enough of the 207,667-record field to foreclose it, but several show sharply falling recent output — a signal worth checking before assuming continued activity.
A wide but not exclusive lead
The top-ranked assignee holds 4,818 records against a field of 207,667. That is a meaningful head start in claim coverage, but it is a fraction of the total record set, not a chokehold on the technology.
The drop-off from top five to top ten is gradual
Fifth place sits at 2,574 records and tenth place at 1,830 — a gentle slope rather than a cliff. That shape means competitive monitoring needs to extend past the obvious names to capture real activity.
Even active filers are pulling back
Several assignees with strong historical filing counts show one or two records in the latest tracked year and year-on-year declines as steep as -91% and -80%. Read this alongside the 18-month publication lag: it likely overstates the slowdown, but the direction is consistent across multiple leaders.
| Assignee | Recent year | YoY |
|---|---|---|
| President and Fellows of Harvard College | 2 | -67% |
| The Trustees of the University of Pennsylvania | 2 | -50% |
| Toray Industries, Inc. | 1 | -80% |
| The Regents of the University of California | 1 | -91% |
| National Cancer Center (Japan) | 1 | -80% |
| E.I. du Pont de Nemours and Company | 0 | — |
| Evogene Ltd. | 0 | — |
| Celera Genomics | 0 | — |
Where to take this from here
The figures above describe the field as a whole. Turning them into a filing or freedom-to-operate decision means running the same search against your own claim language.
Check freedom-to-operate against the cited foundations
The most-cited records in this corpus, including the amplification-process and vector-delivery patents, sit under most later diagnostic and delivery work. Any new filing touching amplification or non-dividing-cell delivery should be checked against them directly.
Run a claim search in EurekaMap your own claim against the IPC composition
With C12N and C12Q carrying the largest share of records, a new filing in genetic engineering or enzymatic testing is entering the densest part of the field. Under-claimed branches like aptamer-based detection or fermentation-based oligonucleotide routes carry less prior art to work around.
Compare IPC coverage in EurekaTrack momentum, not just historical rank
Several top-ranked assignees show steep year-on-year declines in the latest tracked year. Before assuming a competitor's portfolio is still growing, check its recent-year filing rate rather than its cumulative total.
Monitor assignee activity in EurekaFrequently asked questions
The ranked leader in this dataset holds 4,818 records out of 207,667 in scope, with the field then spreading across a long tail of universities, agri-biotech firms and pharmaceutical companies. The top five combined hold 8.5% of all records and the top ten hold 13.3%, so no single company forecloses the space. A practical competitive review should look past the top few names because mid-ranked assignees still hold meaningful, active positions.
Publications peaked in 2021 at 980 and had fallen to 463 by 2024, a -53% change over that complete-year span. That looks like a slowdown, but publication trails actual filing by roughly 18 months, so 2025 and 2026 figures are still incomplete and will rise as records catch up. The safest read is that filing activity cooled from its 2021 peak through 2024, without drawing conclusions about the most recent two years.
Microorganism and genetic engineering claims under C12N lead at 6.2% of the 207,667 records in scope, followed by enzyme- and DNA-based measuring and testing under C12Q at 4.3%, and peptide and protein chemistry under C07K at 3.2%. Medicinal preparations, fermentation-based synthesis, material analysis, nucleic-acid chemistry and therapeutic activity classes each sit below 3%. Because records often carry multiple IPC codes, these figures describe density of claim coverage rather than a strict partition of the field.
Relative to the dense core engineering classes, branches such as aptamer-based fluorescent detection, delivery vectors for non-dividing cells, enzymatic peptide-library synthesis and fermentation-based oligonucleotide production carry lighter claim density in this dataset. That does not mean these areas are unclaimed, only that they sit behind the leading classes in filing volume. A targeted novelty search in the specific sub-area is still the only reliable way to confirm open claim space before filing.
The most-cited record in this corpus is US5130238A, an enhanced nucleic acid amplification process, cited 3,226 times, followed by a vector and delivery method for non-dividing cells and a nucleic acid amplification process. These citation counts reflect age and foundational status more than current commercial relevance, since older patents have simply had more years to accumulate citations. They are best read as a map of which techniques later filings build on, not as a ranking of present-day importance.
Research Synthetic DNA & RNA Patent Landscape in depth with Eureka
Go past this page: query the whole synthetic dna & rna patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.